4:33 PM
 | 
Jun 09, 2010
 |  BC Extra  |  Clinical News

Nektar reports NKTR-102 data

Nektar Therapeutics (NASDAQ:NKTR) said NKTR-102 as a single agent led to an overall response rate of 21%...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >